Trial Profile
A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Stempeutics
- 22 Feb 2017 New trial record